|
|
|
|
1 2 3 4 5 6 7 8 9 10 ... Total pages:244 Next
(China) Ascletis secures China market rights from Janssen for TMC310911, a next-generation HIV protease inhibitor
(BiotechEast staff)
30 April, 2013
China and US-based drug development firm Ascletis today announced that the company has licensed development, manufacturing and commercialization rights from Janssen R&D Ireland for TMC310911, a next-generation HIV protease inhibitor (PI). The agreement provides Ascletis with exclusive rights to develop and commercialize TMC310911 in Greater China, including mainland China and Macau. Janssen will retain all rights in the rest of the world and is eligible to receive royalties based on product sales in Greater China.
|
|
|
|
|
(Taiwan) Medical device sector should look to Israel for inspiration and cooperation: Forum speakers
(BiotechEast staff)
1 May, 2013
Israel and Taiwan are both small-sized technology-focused export-oriented countries, and share a number of traits that bode well for increased cooperation in each other's medical device industries. This was one of several take-home messages from an industry forum held by the Israel Economic and Cultural Office in Taipei on Tuesday. The event was held primarily to promote and encourage medical device industry notables form Taiwan to attend the 2nd 'Med in Israel' international conference being held June 10-13 in Tel Aviv.
|
|
|
|
|
(Taiwan) Work on H7N9 virus still in R&D stage: health official
(Focus Taiwan)
24 April, 2013
The Department of Health (DOH ) said Wednesday that work on the new H7N9 avian flu virus strain obtained from China is still in the research and development stage and that the DOH has invited local experts to discuss ways of combating the deadly flu.
More...
|
|
|
|
|
|
|
Taiwan Life Sciences Bulletin
|
 |
|
 |
|
|
 |
 |
|
 |
|
| |
